Treating Opioid Use Disorder in Adolescents
MEDICATION ASSISTED TREATMENT ECHO
This interactive web-based program provides essential guidelines and steps to implementing and integrating a successful MAT program into an outpatient primary care setting. The MAT program aims to improve access for patients suffering from opioid use disorder.
- Diagnosing Opioid Use Disorder
- Types of medications (naltrexone vs. buprenorphine) and requirements for each (labs, monitoring, etc.)
- Buprenorphine induction maintenance, relapse and tapering protocols
- Referral process, clinic flow
- Opiate withdrawal-treatment
- Drug screens
- Controlled substance agreement
- Multi-party consents
- Prior authorization requirements for buprenorphine (documentation, barriers, etc.)
- Clinic and community integration
The purpose is to inform clinic members (admin, providers, nursing, etc.) on how to successfully integrate a MAT program into an outpatient primary care setting. The mission is to help centers and clinics set up primary care based MAT to improve access for patients suffering from opioid use disorder across the state of Iowa.
Professional Practice Gap
There is a lack of resources, expertise and time for learning the integration of MAT within a primary care setting. By providing access to example protocols, clinic flow and other measures to improve integration, this will decrease the burden of the work required to start a program.
- Identify the major risk factors for developing Opioid Use Disorder (OUD).
- Examine the evidence supporting Medications for treating Opioid Use Disorder (MOUD) in adolescents and young adults.
- Identify strategies to engage youth in treatment.
Deepa R. Camenga, Hector A. Colon-Rivera, Srinivas B. Muvvala. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks. Journal of Studies on Alcohol and Drugs, 2019; 80 (4): 393 DOI: 10.15288/jsad.2019.80.393
Levy S. Youth and the Opioid Epidemic. Pediatrics. 2019;143(2):e20182752
Borodovsky JT, Levy S, Fishman M, Marsch LA. Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review. J Addict Med. 2018;12(3):170-183. doi:10.1097/ADM.0000000000000388
Medication-Assisted Treatment of Adolescents With Opioid Use Disorders COMMITTEE ON SUBSTANCE USE AND PREVENTION Pediatrics Sep 2016, 138 (3) e20161893; DOI: 10.1542/peds.2016-1893
Gagan Lamba, MA, MS, MBA, CSM
Iowa Primary Care Association
J. Craig Allen, MD, FASAM
Medical Director, Rushford
Chief of Psychiatry, MidState Medical Center
Vice President of Addiction Services, Behavioral Health Network
- Medical School: Wayne State University School of Medicine MD
- Internship: Tufts New England Medical Center, Psychiatry
- Residency: Harvard Medical School Massachusetts General Hospital, Child & Adolescent Psychiatry; Tufts New England Medical Center, General Psychiatry
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.25 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and Primary Health Care, Inc. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.25 continuing education contact hour(s). No partial credit awarded.
- Other healthcare professionals: This live activity is designated for 1.25 AMA PRA Category 1 Credit(s)TM.
No commercial interest provided financial support for this continuing education activity.
Relevant to the content of this educational activity, the following individuals have no conflicts of interest with commercial interest companies to disclose.
- J. Craig Allen, MD, FASAM, Speaker
- Daniel Brody, DMD, Speaker
- Nicole Gastala, MD, Planning Committee Member
- Bery Englebretson, MD, Activity Director and Planning Committee Member
- Gagandeep Lamba, MA, MS, MBA, Moderator
- Chelsea Miller, Moderator and Planning Committee Member
- Kathryn Sticca, PharmD, BCPP, Planning Committee Member
The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.25 AMA PRA Category 1 Credits™
- 1.25 AOA Category 2A
- 1.25 CE Contact Hour(s)
- 1.25 IBON